Please Wait
Applying Filters...
menu
    • menu
    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    Munit offers scalable GMP micronization and particle size engineering to enhance drug solubility, bioavailability, and performance.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-04-20

    Virtual Booth

    An Enquiry

    PMC Isochem is your partner for smart CDMOs of Intermediates, APIs, & excipients & a catalog of Intermediates & Generic APIs.

    Virtual Booth

    Contact Supplier

    Expand your portfolio with Egis- value-added generics, API capabilities, and reliable contract services to drive your growth.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-04-20

    Virtual Booth

    An Enquiry

    Menu

    Fingolimod Hydrochloride

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    REF. STANDARDS & IMPURITIES

    ANALYTICAL

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Alembic Announces FDA Final Approval For Fingolimod Capsules
    Alembic Announces FDA Final Approval For Fingolimod Capsules

    27 Apr 2026

    // INDPHARMAPOST

    https://www.indianpharmapost.com/drug-approval/alembic-announces-fda-final-approval-for-fingolimod-capsules-19931

    INDPHARMAPOST
    27 Apr 2026
    Share Share
    Alembic’s Generics Fingolimod HCl Receives Approval in US
    Alembic’s Generics Fingolimod HCl Receives Approval in US

    24 Apr 2026

    // FDA

    https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=207974

    FDA
    24 Apr 2026
    Share Share
    Enforcement Report - Week of July 26, 2023
    Enforcement Report - Week of July 26, 2023

    26 Jul 2023

    // FDA

    https://www.pharmacompass.com/pdf/news/enforcement-report-week-of-july-26-2023-55742.pdf

    FDA
    26 Jul 2023
    Share Share
    US Supreme Court rebuffs Novartis bid to revive MS drug Gilenya patent
    US Supreme Court rebuffs Novartis bid to revive MS drug Gilenya patent

    18 Apr 2023

    // REUTERS

    https://www.reuters.com/legal/us-supreme-court-rebuffs-novartis-bid-revive-ms-drug-gilenya-patent-2023-04-17/

    REUTERS
    18 Apr 2023
    Share Share
    Vyne swings behind BET, seeks partner for failed eczema drug
    Vyne swings behind BET, seeks partner for failed eczema drug

    10 Mar 2023

    // Nick Paul Taylor FIERCE BIOTECH

    https://www.fiercebiotech.com/biotech/vyne-swings-behind-bet-inhibitors-seeks-partner-failed-eczema-drug

    Nick Paul Taylor FIERCE BIOTECH
    10 Mar 2023
    Share Share
    Drug, TASCENSO ODT , Launched to Meet the Needs of Multiple Sclerosis Patients
    Drug, TASCENSO ODT , Launched to Meet the Needs of Multiple Sclerosis Patients

    13 Feb 2023

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20230213005286/en

    BUSINESSWIRE
    13 Feb 2023
    Share Share
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.